Corporate Governance
Shareholder & stock info
Transactions
Today, tumor recurrence is the main cause of cancer-related deaths. We aim to reduce tumor recurrence by harnessing the immune system to act against residual cancer cells.
We apply our understanding of dendritic cell biology to design cancer immunotherapies that stimulate active immunity, the only long-lasting form of immunity.
Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
At Mendus, we share a strong commitment to improve the lives of people with cancer. And we do it as a team who values honesty and togetherness. Join us and help change cancer treatment at its core.
